BackProtagenic Therapeutics Overview

Protagenic Therapeutics Receivables

Track Protagenic Therapeutics's receivables ($0) with charts, peers, and YoY trends.

Get informed when a big investor buys or sells

+ Follow
Receivables
$0.00

Peer average

Loading

Protagenic Therapeutics Receivables History

Loading

Protagenic Therapeutics vs. peers: Receivables Comparison

Loading

Protagenic Therapeutics Receivables Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Balance Sheet Breakdown

Current CashShort Term InvestmentsReceivablesInventoryOther Current AssetsCurrent AssetsLong Term InvestmentsProperty Plant EquipmentGoodwillIntangible AssetsOther AssetsTotal AssetsNet Tangible AssetsAccounts PayableOther Current LiabilitiesTotal Current LiabilitiesLong Term DebtOther LiabilitiesMinority InterestTotal Liabilities

Protagenic Therapeutics (PTIX) FAQ

As of the most recent data (December 2025), PTIX shows a receivables of $0. In the prior-year period, the figure was $0. Scroll down for historical charts and peer comparison views.

Compared with the year-ago period, PTIX's receivables is now $0 (was $0). Pairing that YoY change with peer averages gives a clearer picture of whether Protagenic Therapeutics is outperforming or lagging.

Tracking PTIX's receivables over time shows whether Protagenic Therapeutics is scaling, shrinking, or reshaping that part of the business. The current reading is $0 In the prior-year period, the figure was $0. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.

Besides this receivables page, Stockcircle has Protagenic Therapeutics's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect receivables (currently $0) with ownership activity and broader fundamentals.

Protagenic Therapeutics's receivables is $0; compare it with other Industrials names on the peer chart. Typical ranges vary by sub-industry, so always sanity-check against the closest competitors, not just the whole sector bucket.